Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2024 13:20 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted...
November 06, 2024 08:30 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18...
October 17, 2024 08:45 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
October 09, 2024 08:45 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet to receive $1.0 million in upfront payment and up to an additional$1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India...
October 04, 2024 08:30 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
September 30, 2024 09:00 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Provides interested parties the ability to ask questions and submit...
September 25, 2024 08:30 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted...
September 18, 2024 08:30 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE...
September 04, 2024 09:15 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
August 19, 2024 08:45 ET | Source: Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy An Innovative Immuno Oncology...